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Abstract
 
An unresolved issue in the field of T helper (Th) cell development relates to the findings that
low doses of antigen promote Th2 cell development in vitro, whereas several classic in vivo
studies suggest the opposite. Here we resolve this paradox by studying the early immune response
in mice after infection with different doses of 
 
Leishmania major
 
. We found that low parasite
doses induced a Th2 response in C57BL/6 (B6) mice, whereas high doses induced a Th1 response.
However, the Th2 response in low dose–infected mice was transient and the animals healed.
The appearance of a Th1 response after low dose infection was dependent upon the concomitant
activation of interferon 
 
 
 
–producing CD8
 
  
 
T cells. In the absence of CD8
 
  
 
T cells, the Th2
response was maintained. However, either neutralization of interleukin (IL)-4 or administration
of IL-12 promoted a Th1 response after low dose infection of CD8-deficient mice, indicating
that the required role for CD8
 
  
 
T cells was limited to modulation of CD4
 
  
 
T cell responses.
Thus, the discrepant results seen between in vivo and in vitro studies on the effects of antigen
dose on Th cell differentiation may depend upon whether CD8
 
  
 
T cells participate in the
immune response.
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Introduction
 
The effect of antigen dose on the development of CD4
 
 
 
Th1 and Th2 cells is controversial, as some reports suggest
that high and low antigen doses promote Th1 and Th2
responses, respectively, whereas others suggest the oppo-
site. Resolving this controversy is of importance for the
development of vaccines as well as immunotherapies directed
at modulating Th1 and Th2 responses. Most in vitro results
indicate that lower antigen doses favor a Th2 response,
whereas higher doses favor a Th1 response (1–5). For ex-
ample, in vitro stimulation of TCR transgenic CD4
 
  
 
T
cells with low peptide doses induced an IL-4 response,
whereas higher doses led to increased IFN-
 
  
 
production (1,
4). On the other hand, although some in vivo studies indi-
cate that low antigen doses favor a Th2 response, several
others suggest the opposite (6–8). A classic experiment that
addressed antigen dose found that daily injections of flagellin
in rats was associated with the dose-dependent develop-
ment of either delayed-type hypersensitivity or antibody
responses, with high doses favoring antibody responses and
lower doses favoring a delayed-type hypersensitivity response
(6, 7). One explanation for these discrepant results might
be that the in vitro studies measured the response of isolated
CD4
 
  
 
T cells, whereas the in vivo response was assessed in the
presence of cells (such as NK cells, CD8
 
  
 
T cells, etc.) that
might modulate the response.
The outcome of infection with the protozoan parasite
 
Leishmania major
 
 is dependent upon whether CD4
 
  
 
Th1 or
Th2 cells develop after infection, and experimental infec-
tions in mice with 
 
L. major
 
 have been used extensively to
define the factors that regulate Th1 and Th2 cell develop-
ment (9, 10). In resistant C57BL/6 (B6) mice, production
of IFN-
 
  
 
by Th1 cells leads to parasite control, whereas
BALB/c mice develop a Th2 response and a progressive
disease. In contrast to CD4
 
  
 
T cells, CD8
 
  
 
T cells have
been thought to play only a secondary role in resistance to
 
L. major
 
 (11, 12). However, it was recently found that in
the absence of CD8
 
  
 
T cells, C57BL/6 mice are unable to
heal after low dose 
 
L. major
 
 infection (13). This result has
prompted us to reexamine the influence of antigen dose on
the development of Th1 and Th2 cells in vivo, and to in-
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vestigate the possible regulatory role of CD8
 
  
 
T cells on
Th cell development. At present, the prevailing thought is
that low doses of 
 
L. major
 
 promote a Th1 response, based
on the finding that although BALB/c mice infected with
high parasite doses develop an uncontrolled infection, a
protective Th1 response is induced after low dose infection
(14, 15).
Here we report that low dose 
 
L. major
 
 infection of
B6 mice primes CD4
 
  
 
T cells for Th2 cell development.
However, 
 
L. major
 
 concomitantly activates IFN-
 
 
 
–produc-
ing CD8
 
  
 
T cells, which promotes a switch from the
CD4
 
  
 
Th2 response to a protective Th1 response. Thus,
our results unveil an important role for CD8
 
  
 
T cells as
regulators of CD4
 
  
 
Th1 cell development, suggesting that
low antigen doses may preferentially promote a CD4
 
  
 
Th2
response in vivo, but in situations where CD8
 
  
 
T cells
are concomitantly activated this Th2 response might be
masked. These findings have direct implications for how
vaccines or immunotherapies might be administered to
preferentially develop a Th1 or Th2 response.
 
Materials and Methods
 
Mice.
 
6–8 wk old female C57BL/6 (B6), homozygous CD8
 
 
 
(B6. 129S2-cd8a
 
tmimak
 
, CD8 KO), IFN-
 
  
 
(B6.129S7-Ifng
 
tm1Ts
 
,
 
 
 
-KO), and 
 
 
 
-2 microglobulin (B6. 129P2-
 
 
 
2m
 
tmiUnc
 
, 
 
 
 
2m
KO)–deficient mice were purchased from The Jackson Labora-
tory. All mice were maintained in a specific pathogen-free envi-
ronment at the University of Pennsylvania Animal Care Facilities.
 
Parasites and Antigen. L. major
 
 parasites (MHOM/IL/80/Fried-
lin) were grown in Grace’s insect medium (Life Technologies)
supplemented with 20% heat-inactivated FBS, 2 mM glutamine,
100 U/ml penicillin, and 100 
 
 
 
g/ml streptomycin. For infection,
7-d stationary phase promastigotes were washed three times in
PBS and counted. Mice were infected by injecting 10
 
6 
 
(high
dose) or 10
 
3 
 
(low dose) parasites suspended in 10 
 
 
 
l PBS in the ear
(intradermal), and the course of lesion progression was monitored
weekly by measuring the diameter of ear induration with vernier
calipers (Thomas). In some experiments, mice were infected with
low dose parasites suspended in 10 
 
 
 
l PBS containing leishmanial
antigen (10
 
6 
 
freeze-thawed 
 
L. major
 
).
 
In Vivo Anti–IL-4 mAb and rIL-12 Treatment.
 
Mice were treated
intraperitoneally with 2 mg anti–IL-4 antibody (11B11) in PBS
given at the time of infection and then once weekly for 3 wk.
Control mice were given the same concentration of rat IgG in
PBS. Recombinant IL-12 (0. 5 
 
 
 
g/mouse per injection; pro-
vided by J. Sypek and S. Wolf, Wyeth Discovery Research,
Cambridge, MA) was given first at the time of infection (mixed
with parasites) and at 3 and 6 d after infection intraperitoneally.
Control mice received injections of PBS.
 
CD8
 
  
 
T Cell Purification and Adoptive Transfer.
 
B6 mice and
IFN-
 
 
 
–deficient mice were depleted of CD4
 
  
 
T cells by injec-
tion of 1 mg anti-CD4 mAb (GK1.5) 1 and 3 d before mice were
killed. This treatment routinely depletes 
 
 
 
98% of CD4
 
  
 
T cells
when assessed by flow cytometry. Pooled single cell suspensions
of spleens and lymph nodes were depleted of red blood cells by
lysing with ammonium chloride lysis buffer, and CD8
 
  
 
T cells
were purified using T cell columns (R&D Systems) according to
the manufacturer’s recommendations. 10
 
7 
 
purified CD8
 
  
 
T cells
were transferred intravenously into naive CD8-deficient mice
that were then infected the next day with 10
 
3 
 
L. major
 
.
 
In Vitro Recall Response.
 
At various times after infection, ret-
romaxillary lymph nodes were harvested and made into single
cell suspensions. Cells were washed, resuspended at 4 
 
  
 
10
 
6
 
/ml
in complete medium (DMEM supplemented with 10% heat-
inactivated FBS, 25 mM Hepes, 5 
 
  
 
10
 
 
 
5 
 
M 2-ME, 2 mM gluta-
mine, 100 U/ml penicillin, and 100 
 
 
 
g/ml streptomycin), and
plated at 1 ml/well in 24-well tissue culture plates (Falcon Prod-
ucts). Cells were stimulated with or without 50 
 
 
 
g/ml soluble
leishmanial antigen (SLA). To facilitate the detection of IL-4, 5
 
 
 
g/ml anti–IL-4R blocking mAb (M1; provided by F. Finkel-
man, University of Cincinnati, Cincinnati, OH, and Immunex)
was added to prevent autocrine consumption of IL-4. The cul-
ture supernatant fluids were collected after 72 h and stored at
 
 
 
70
 
 
 
C until they were assayed for cytokines by ELISA.
 
Cellular Proliferation and Intracellular Cytokine Staining.
 
To assess
cellular proliferation and intracellular cytokine accumulation, cells
were labeled with carboxyfluorescein diacetate succinimidyl ester
(CFSE) dye and cultured in 96-well round-bottom culture plates
(2 
 
  
 
10
 
5
 
/well in 200 
 
 
 
l aliquots) in the presence of 50 
 
 
 
g/ml
SLA. After 5 d, cells were stimulated with 50 ng/ml PMA and
500 ng/ml ionomycin for 5 h. 10 
 
 
 
g/ml brefeldin A was added
in the last 2 h to enhance intracellular cytokine protein accumu-
lation. Cells were harvested and stained for cell surface markers
and intracellular cytokines (16).
 
Cytokine ELISAs.
 
IL-4 and IFN-
 
  
 
concentrations in culture
supernatants were measured by sandwich ELISA as described pre-
viously (17). The levels of detection of the ELISA were 0.4 U/ml
and 30 pg/ml for IL-4 and IFN-
 
 
 
, respectively.
 
Estimation of Parasite Burden.
 
The parasite burden in the ear
was quantified as described previously (18) with minor modifica-
tions. In brief, the dorsal and ventral layers of the ear were sepa-
rated with forceps and incubated for 30 min at 37
 
 
 
C in complete
Grace’s medium containing 1 mg/ml collagenase/dispase (Sigma-
Aldrich). Thereafter, the ears were minced and homogenized in 2
ml Teflon-coated tissue grinder and the homogenate was serially
diluted (1:2) in 96-well plates and incubated at 26
 
 
 
C. The num-
ber of viable parasites in each tissue was calculated from the high-
est dilution at which parasites were observed after 7 d.
 
Statistical Analysis.
 
A two-tailed Student’s 
 
t
 
 test was used to
compare means of lesion sizes, parasite burdens, and cytokine
production from different groups of mice. Differences were con-
sidered significant at P 
 
  
 
0.05.
 
Results
 
Low Dose L. major Infection Promotes Th2 Responses.
 
To in-
vestigate the influence of parasite dose on the development
of CD4
 
  
 
T cells in vivo, B6 mice were infected with either
10
 
3 
 
or 10
 
6 
 
L. major
 
 intradermally in the ear. After 3 wk, cells
from the draining lymph nodes of infected mice were CFSE
labeled to monitor proliferation and stimulated with SLA.
CD4
 
  
 
T cells from mice infected with a high dose of para-
sites exhibited substantial antigen-specific proliferation (Fig.
1 A). In addition, intracellular cytokine staining indicated
that a large percentage of the CD4
 
  
 
T cells produced IFN-
 
 
 
,
whereas few cells produced IL-4 (Fig. 1 B). In contrast, cells
from low dose–infected mice proliferated less well, and a
smaller percentage of cells made IFN-
 
 
 
. However, a signifi-
cantly higher percentage of cells from low dose–infected
mice made IL-4. This pattern of response was also observed
when cytokine production was measured by ELISA. Cells 
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from low dose–infected mice produced more IL-4 and less
IFN-
 
 
 
, whereas those from high dose–infected mice pro-
duced no IL-4, but high levels of IFN-
 
  
 
(Fig. 1 C). Thus, at
this early time point, the CD4
 
  
 
T cell response in B6 mice
infected with low doses of 
 
L. major
 
 is strongly biased toward
a Th2 response. Nevertheless, as reported previously (13,
15), low dose infections were associated with healing and ef-
fective parasite control several weeks after infection (Fig. 1 D
and unpublished data). Furthermore, when the immune re-
sponse was assessed in the healed mice, both low and high
dose–infected mice exhibited an enhanced IFN-
 
  
 
response,
indicating that the dominant CD4
 
  
 
Th2 response seen in
low dose–infected mice was transient (Fig. 1 E).
 
Low Dose L. major Infection Leads to a Sustained Th2 Re-
sponse in the Absence of CD8
 
  
 
T Cells.
 
Because the Th2 re-
sponse induced by low dose infection was transient, we
explored the possibility that non-CD4
 
  
 
T cells responding
to 
 
Leishmania
 
 antigen may regulate Th cell responses. We
found that both high and low dose 
 
L. major
 
 infections were
associated with a robust CD8
 
  T cell proliferative response
(Fig. 2 A), and a significant percentage of these CD8  T
cells produced IFN-  (Fig. 2 B). Therefore, we hypothe-
sized that CD8  T cells might contribute to reversing the
early Th2 response seen in low dose L. major infection.
Consistent with this idea was a recent finding that CD8  T
cells are required for healing a low dose infection with L.
major (13). However, this contrasts with several previous
studies demonstrating that CD8  T cells are not required for
control of a primary infection (19–21). To determine if the
discrepancy in these results was related to infection dose,
and whether IFN- –producing CD8  T cells were in-
volved in modulating the initial Th2 response, we infected
CD8  T cell–deficient mice, both CD8 and  2m KO ani-
mals, with low or high doses of L. major. Similar to infected
WT mice, at 3 wk after infection cells from low dose–
infected CD8 T cell–deficient mice produced more IL-4 and
less IFN- , whereas those from high dose–infected mice
produced no IL-4, but high levels of IFN-  (unpublished
data). Neither CD8 nor  2m-deficient mice were able to
resolve disease after low dose infections, whereas high dose
infection was associated with disease resolution in both
strains of mice (Fig. 2, C and D). Consistent with a role for
Figure 1. Parasite dose influences the development of CD4  T cell
responses in vivo. (A) Antigen-specific proliferation by CD4  T cells is
diminished in low dose–infected mice. B6 mice were infected intrader-
mally with a low (103) or high (106) dose of L. major. 3 wk after infection,
mice were killed and cells isolated from the retromaxillary draining lymph
node (dLN) were CFSE labeled, stimulated for 5 d with SLA, and ana-
lyzed for proliferation by flow cytometry by gating on live CD4  cells.
(B) Low dose L. major infection induces an early CD4  Th2 response.
Cells from A above were also stained for intracellular IFN-  and IL-4.
(C) Levels of IFN-  and IL-4 in 72-h culture supernatant fluids of lymph
node cells from A above. (D and E) The early low dose–induced Th2
response in B6 mice is transient. B6 mice infected with a low or high
dose of L. major were monitored weekly for the development and pro-
gression of cutaneous lesion (D). 16 wk after infection and resolution of
lesion, mice were killed and cells from the dLN were stimulated with
SLA for 72 h. The supernatant fluid was then assayed for IFN-  and IL-4
by ELISA (E). Representative data from three experiments with similar
results are presented.
Figure 2. CD8  T cells are required for downmodulation
of low dose–induced Th2 responses and susceptibility to L.
major. (A and B) L. major infection induces proliferation
and IFN-  production by CD8  T cells in B6 (WT) mice.
The dLN cells from B6 mice infected with low and high
dose L. major for 3 wk were labeled with CFSE, stimulated
with SLA for 5 d, and stained for intracellular IFN- . (A) Pro-
liferation (gated on live CD8  cells) and (B) IFN-  pro-
duction by CD8  T cells was analyzed by flow cytometry.
(C and D) CD8  T cells are required for resistance to low
dose, but are dispensable for high dose L. major infection.
Course of lesion progression (C) and parasite burden (D) in
the ear of WT, CD8, and  2m-deficient mice infected
with low and high dose L. major. (E) In the absence of
CD8  T cells, the low dose–induced Th2 response is sus-
tained. CD8-deficient mice infected with low and high
doses of L. major were killed at 13 wk, the dLN cells were
stimulated with SLA for 3 d, and the production of IFN- 
and IL-4 was measured by ELISA. Representative data
from three experiments with similar results are presented.Low Dose L. major Promotes Th2 Responses 1562
CD8  T cells in down-regulation of Th2 responses, at 13
wk IL-4 production by cells from low dose–infected CD8-
deficient mice was significantly greater than that produced
by cells from WT mice (Fig. 2 E). Correspondingly, the
IFN-  response in low dose–infected CD8-deficient ani-
mals remained low relative to either low dose–infected WT
mice or either mouse strain infected with a high dose of
parasites (Fig. 2 E). These results strongly implicate CD8  T
cells as important for down-regulating the early Th2 re-
sponse in low dose–infected mice.
Leishmanial Antigen Overcomes the Dependence on CD8  T
Cells for Resolution of Low Dose Infections. To determine if
simply increasing the antigen dose rather than increasing the
number of live parasites could promote a Th1 response, we
characterized the CD4  T cell response of B6 and CD8-
deficient mice infected with a low dose of live parasites mixed
with a high dose of leishmanial antigen. Because similar re-
sults were obtained from both mice, only data from CD8-
deficient mice are presented. After administration of high
doses of antigen in the form of killed parasites, CD4  T cell
proliferation, and the percent of those cells producing
IFN- , was equivalent to that seen with a high dose of live
L. major (Fig. 3, A and B). Similarly, IFN-  and IL-4 pro-
duction analyzed by ELISA indicated that high antigen
doses promoted a Th1 response (Fig. 3 C), suggesting that
the critical factor in CD4  T cell activation is the dose of
antigen and not whether the parasites are alive.
To test if the increase in IFN-  produced by CD4  T
cells was sufficient to overcome the requirement for CD8 
T cells in a low dose infection, we assessed the outcome of
infection in low dose–infected CD8-deficient mice given
leishmanial antigen. Although CD8-deficient mice given a
low dose of L. major developed nonhealing lesions, the
same dose of L. major given with antigen was associated
with a healing infection (Fig. 3 D). In fact, control of the
infection was greater than that observed in WT mice given
a low dose, which would be expected if the high dose of
dead parasites increased the CD4  Th1 response. These re-
sults indicate that by increasing the antigen dose at the time
of initial CD4  T cell priming, sufficient CD4  Th1 cells
can be activated to preclude a need for CD8  T cells.
CD8  T Cells Are Not Required for Healing a Low Dose In-
fection if Th2 Cell Development Is Blocked. If CD8  T cells
are only necessary to modulate the Th2 response induced
by exposure to low doses of antigen, then blocking Th2
cell development by other means should eliminate the re-
quirement for CD8  T cells. To test this, we treated CD8-
deficient mice with either neutralizing anti–IL-4 mAb or
IL-12. In contrast to untreated animals, CD8-deficient
mice depleted of IL-4 were able to heal their low dose in-
fections with the same kinetics as that seen in B6 mice, and
exhibited a reduced parasite burden (Fig. 4 A). The healing
response seen in low dose CD8-deficient infected mice that
were treated with anti–IL-4 was associated with enhanced
IFN-  responses and decreased IL-4 responses (Fig. 4 B).
Similarly, low dose–infected CD8-deficient mice treated
with IL-12 failed to develop disease, effectively controlled
their parasites, and exhibited a Th1 response (Fig. 4, C and
D). Taken together, these results indicate that the condi-
tional requirement for CD8  T cells in a low dose infection
is due to their role in reversing the initial Th2 response and
that if this response is blocked, CD8  T cells are unneces-
sary for lesion resolution.
The Protective Effect of CD8  T Cells Is Mediated by IFN- .
The data above suggests that CD8  T cells are required for
down-regulating the initial Th2 response by proliferating
and producing IFN- , although it is possible that other
IFN- –independent mechanisms might be involved. To
directly address this, we adoptively transferred CD8  T
cells from B6 or IFN- –deficient mice into CD8-deficient
Figure 3. Leishmanial antigen overcomes the dependence on CD8  T
cells for resolution of low dose infections. CD8-deficient mice infected
with a low dose, a high dose, or a low dose of L. major suspended in 106
freeze-thaw parasites (low dose plus antigen) were killed at 3 wk and the
dLN cells were labeled with CFSE, stimulated with SLA for 5 d, and
stained for intracellular IFN- . Proliferation (A) and intracellular IFN- 
secretion (B) by CD4  T cells from infected mice. (C) Some cells were
stimulated with SLA for 72 h and the supernatant fluids were collected
and assayed for IFN-  and IL-4 production by ELISA. (D) Enhanced
resistance in CD8-deficient mice infected with low dose L. major mixed
with leishmanial antigen. CD8-deficient mice were infected with a low
dose of L. major or a low dose given with leishmanial antigen as described
above, and lesion size was measured weekly. Some low dose–infected B6
(WT) mice were included as positive control. Data presented are a repre-
sentative of two experiments with similar results.Uzonna et al. 1563
mice and infected them with a low dose of L. major. As ex-
pected, recipients of WT CD8  T cells resolved their le-
sions and efficiently controlled parasite replication. In con-
trast, mice that received cells from IFN- –deficient mice
developed progressive disease similar to PBS controls (Fig.
5 A). Corresponding with the outcome of infection, adop-
tive transfer of WT CD8  T cells promoted the develop-
ment of a Th1 response, whereas mice that received IFN-
 –deficient CD8  T cells exhibited cytokine levels similar
to unreconstituted CD8-deficient mice (Fig. 5 B). These
data demonstrate that the protective effect of CD8  T cells
during low dose infections is mediated by their production
of IFN- , which down-regulates the initial Th2 response
and enhances Th1 cell development.
CD8  T Cells Are Not Required to Control a Low Dose In-
fection in Immune Mice. The observation that CD8  T cells
are required for resistance against low dose L. major infec-
tion has implications for vaccination strategies against leish-
maniasis. Natural infections are initiated by inoculation of
low numbers of parasites by the sandfly, which raises the
question whether a vaccine targeting CD4  T cells would
be sufficient to mediate resistance to L. major. Indeed, sev-
eral vaccine studies have found that CD8  T cells are im-
portant for optimal resistance to L. major (22–24). However,
whether CD8  T cells are an obligatory requirement or are
necessary due to suboptimal CD4  T cell induction is un-
clear. To address this issue, we asked whether CD8-defi-
cient mice that controlled a high dose L. major infection
could mount a protective secondary response to low dose
challenge. Therefore, B6 and CD8-deficient mice were in-
fected with a high dose of L. major. 6 mo after the primary
infection, these healed mice and their age-matched naive
controls were challenged with a low dose of L. major. As ex-
pected, naive CD8-deficient mice challenged with low dose
L. major developed progressive disease, whereas naive B6
mice developed small lesions that eventually resolved. In
contrast, both healed B6 and CD8-deficient mice devel-
oped minimal lesions after challenge and the lesions con-
tained few parasites (Fig. 6). These results indicate that if
sufficient CD4  T cell immunity is generated, its efficacy
and durability are independent of CD8  T cells. However,
Figure 4. CD8  T cells are not required for
healing a low dose infection if Th2 cell develop-
ment is blocked. (A) Anti–IL-4 mAb promotes
healing in low dose–infected CD8-deficient mice.
CD8-deficient mice infected with a low dose of L.
major were injected intraperitoneally with 2 mg
anti–IL-4 mAb ( ) or control rat IgG ( ) at the
time of infection and weekly thereafter for 3 wk.
Mice were monitored weekly for lesion size and
killed at 11 wk to determine parasite burden. (B)
Anti–IL-4 mAb treatment blocks the low dose–
induced Th2 response. At the time of death, dLN
cells were stimulated with SLA and the supernatant
fluids were assayed for IFN-  and IL-4 by ELISA.
(C) IL-12 promotes healing in low dose–infected
CD8-deficient mice. CD8-deficient mice were in-
fected with a low dose of L. major resuspended in
0.5  g IL-12. Infected mice received additional in-
jections of 0.5  g IL-12 or PBS intraperitoneally
on days 3 and 6, and lesion size was monitored
weekly. 11 wk after infection, mice were killed to
estimate parasite burden in the ear. (D) IFN-  and
IL-4 production by dLN cells from IL-12– and
PBS-treated mice after in vitro stimulation with
SLA. Data presented are a representative of two ex-
periments with similar results.
Figure 5. The protective effect of CD8  T cells is mediated by IFN- .
(A) CD8-deficient mice were given PBS (CD8 KO) or 107 purified
CD8  T cells from B6 (& WT) or IFN- –deficient (&  -KO) mice, and
infected with a low dose of L. major the next day. The course of lesion
progression was monitored and 14 wk after infection mice were killed to
determine parasite burden. (B) CD8  T cells from WT, but not IFN- –
deficient, mice inhibit the low dose–induced Th2 response. At the time
of death, dLN cells were stimulated with SLA for 72 h and the superna-
tant fluids were assayed for IFN-  and IL-4 production by ELISA. Data
presented are a representative of two experiments with similar results.Low Dose L. major Promotes Th2 Responses 1564
whether this only applies to mice that maintain persistent
parasites, which would be the case here, has yet to be tested.
Discussion
Understanding how antigen dose influences the devel-
opment of Th1 and Th2 cells is important for designing
vaccines and to date, experiments that have addressed this
issue have had conflicting results. Several in vitro studies
using TCR transgenic T cells show that low doses of anti-
gen favor the generation of Th2 cells, whereas high doses
favor Th1 cells (1–4). In contrast, the effect of antigen dose
on the development of CD4  Th cells in vivo is less clear.
Although some studies indicate that low and high antigen
doses favor Th1 and Th2 cell development, respectively (6,
7, 14, 15), others show the reverse (5, 8). In this study, we
provide an explanation for these conflicting results. We
find that low doses of L. major parasites promote the expan-
sion of Th2 cells, but that due to the concomitant produc-
tion of IFN-  by CD8  T cells, the Th2 response is tran-
sient. Thus, in the absence of CD8  T cells, or in cases
where CD8  T cells are not stimulated, low doses of anti-
gen might promote a Th2 response, not only in vitro, but
also in vivo. Our observation that low dose infection in-
duces a Th2 response is also consistent with several reports
that show that the development of allergic airway disease in
the murine model of atopic asthma is associated with low
dose allergen sensitization resulting in high levels of IL-4
and IgE production, and can be blocked by high dose anti-
gen sensitization (25–27).
A role for CD8  T cells in resistance to leishmaniasis has
been described, but not linked with the effects of parasite
dose on Th cell development. For example, CD8  T cells
contribute to optimal resistance in a secondary infection (11,
28), to vaccine-induced immunity (22–24), and more re-
cently were reported to be required for resistance to a pri-
mary infection (13). The function of CD8  T cells in these
systems could involve cytotoxicity because Leishmania-spe-
cific cytotoxic T cells capable of directly lysing infected
macrophages have recently been cloned from mice infected
or vaccinated with Leishmania amazonensis (29, 30). How-
ever, in our studies it is more likely that the ability of CD8 
T cells to make IFN-  contributes to the resistance observed
because CD8  T cells from IFN- –deficient mice were un-
able to promote healing. CD8  T cell–derived IFN-  might
be important for activating macrophages to kill L. major, par-
ticularly because CD8  T cells accumulate in lesions of mice
infected with L. major (13). However, we would argue that
the critical function for CD8  T cell–derived IFN-  is to
modulate the Th2 response because blockade of Th2 re-
sponses in CD8-deficient mice by other means promoted
resistance in low dose–infected mice. Similarly, the role of
CD8  T cells in vaccine-induced immunity has been shown
to involve IFN-  production (23). These results are consis-
tent with findings where it was found that CD8  T cells
switched an immune response from a humoral to a cell-
mediated mode (31), contributed to maintaining a CD4  Th1
response in an allograft-rejection model (32), inhibited IL-4
production by CD4  T cells (33), and in viral infections pro-
moted CD4  Th1 cell development in an IFN- –depen-
dent manner (34, 35). Taken together, the data strongly fa-
vor a role for CD8  T cell–derived IFN-  in promoting a
Th1 response and resistance after low dose infection.
CD8  T cell–derived IFN-  could influence Th1 cell
development indirectly via enhancement of IL-12 produc-
tion by DCs (36) or through the production of proinflam-
matory chemokines (37, 38). Another effect of CD8  T
cell–derived IFN-  in augmenting the Th1 response could
involve increased STAT-1 activation in CD4  T cells,
leading to increased T-bet, IFN- , and IL-12 receptor ex-
pression. (39, 40). Consistent with this role for IFN- ,
were findings in an immunization model suggesting that
CD8 -derived IFN-  was important in maintaining IL-12
receptor expression (23). We favor this role for IFN-  be-
cause increased IL-12 signaling would not only enhance
the IFN-  response, but might lead to the preferential ex-
pansion of Th1 cells in response to IL-12, contributing to
the shift in the Th cell response from a Th2 to a Th1 re-
sponse over time.
An important experiment showing the influence of anti-
gen dose on CD4  Th cell development in an infectious
disease model came from the work of Bretscher et al. (14),
who found that low dose L. major infection induces Th1
cell development and resistance in the highly susceptible
BALB/c mouse. We were unable to investigate the role of
CD8  T cells in low dose healing in BALB/c mice because
in our laboratory, and some others (41, 42), BALB/c mice
infected with low doses of L. major failed to heal (unpub-
lished data). The use of different L. major strains may ac-
count for these divergent results (43, 44). Many factors
contribute to the development of Th cell subsets in leish-
maniasis (9, 10), and we would argue that the influence of
dose is subordinate to one of these factors in BALB/c mice.
Nevertheless, although we were unable to directly test the
role of CD8  T cells in the resistance seen to low dose in-
Figure 6. CD8  T cells are not required to control a low dose infection
in immune mice. B6 (WT) and CD8-deficient (KO) mice (five mice per
group) were infected with 106 (high dose) L. major and allowed to heal.
6 mo after primary infection, healed mice together with some naive con-
trols (five mice each) were challenged with 103 L. major and the course of
lesion progression was monitored. 10 wk after challenge mice were killed
to estimate parasite burden. Data presented are a representative of two ex-
periments with similar results.Uzonna et al. 1565
fection, other studies support the idea that CD8  T cells are
important to resistance in BALB/c mice. Thus, the ability
of BALB/c mice to develop a Th1 response and resistance
to L. major after vaccination with LACK DNA, which ar-
guably would constitute a low dose of antigen, is com-
pletely dependent upon CD8  T cells (22, 23).
The requirement for CD8  T cells to resolve a low dose
infection, as well as other reports that showed that immunity
after vaccination with LACK DNA (22, 23) or heat-killed
L. major in CpG adjuvant (24) depends on CD8  T cells, has
implications for vaccination against leishmaniasis. Our data
indicates that one way CD8  T cells promote resistance
is by blocking the development of a CD4  Th2 response.
Whether this is the case in vaccine models is unclear, but
studies using CpG as an adjuvant indicate that IFN-  pro-
duction from CD8  T cells is required. Interestingly, the re-
quirement for CD8  T cells was observed both at the vacci-
nation stage and the challenge stage (23). In contrast, we
found that if immunity was induced by a high dose infec-
tion, CD8  T cells were not required at the time of chal-
lenge. This may indicate that if a large CD4  T cell response
is generated, CD8  T cells may not be required to maintain
immunity. On the other hand, the durability of infection-
induced resistance may differ from vaccine models because
L. major persists after resolution of disease and therefore can
contribute to the continuous activation of effector CD4  T
cells (45, 46). In any event, it is likely that optimal protec-
tion will depend on the activation of both CD4  and CD8 
T cells, and our data elucidates one of the mechanisms by
which CD8  T cells contribute to immunity.
In summary, we have shown that low doses of L. major
induce a transient Th2 response, which is modulated by
CD8  T cells over several weeks of infection. These find-
ings may in part explain why under natural conditions,
where sand flies inoculate low numbers of parasites, the de-
velopment of immunity can take several weeks (18). More
importantly, they indicate that the discrepancy between in
vivo and in vitro findings on the role of antigen dose in Th
cell development can be explained by whether CD8  T
cells are concomitantly activated. Antigen dose is an impor-
tant component in Th cell development and our results
provide additional insights into how dose might influence
the efficacy of vaccines and immunotherapies.
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